Gain Therapeutics, Inc. 8-K

What Happened

• Gain Therapeutics, Inc. filed an 8-K on May 26, 2026 to disclose interim clinical and biomarker results from Part 2 (the nine‑month extension) of its Phase 1b open‑label study of GT-02287 in Parkinson’s disease. The data were presented orally at the 3rd International GBA1 Meeting (May 22–23, 2026) in Phoenix, AZ.
• A Data Monitoring Committee reviewed the study on March 5, 2026 and recommended the trial continue without changes. Sixteen of 19 participants who completed Part 1 entered the extension; all 16 remained on study and had completed five months of dosing (Day 150) at the time of reporting.

Key Details

• In participants with elevated baseline cerebrospinal fluid (CSF) glucosylsphingosine (GluSph), GluSph levels decreased by an average of 81% after 90 days of treatment with GT-02287.
• DOPA decarboxylase (DDC) levels decreased after 90 days in those with high baseline CSF GluSph; elevated DDC is associated with Parkinson’s dopaminergic dysfunction.
• At Day 150, patients with high baseline GluSph showed a 4.8‑point greater improvement in the sum of MDS‑UPDRS Part II + Part III scores versus those with low baseline GluSph; overall MDS‑UPDRS scores remained stable across the study population.
• Participants reported unsolicited perceived benefits after 90 days: four noted improved smell/taste, four noted improved balance/gait, and three noted improved sleep. Planned Phase 2 endpoints will include UPSIT smell testing and Opal wearable sensors for gait assessment.

Why It Matters

• The filing shows early clinical and biomarker signals (large GluSph reductions and clinical score differences tied to baseline biomarker levels) that support continued development of GT‑02287 for Parkinson’s disease. For investors, these results are relevant because they address both target engagement (GluSph) and potential clinical effects in a well‑defined small cohort.
• The DMC decision to continue without changes and retention of all extension participants through Day 150 reduce near‑term operational risk. Planned Phase 2 assessments (objective smell testing and wearable gait measures) indicate the company intends to gather more rigorous, quantifiable endpoints in later studies.